{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:12:16Z","timestamp":1790460736213,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.dld.2025.07.019","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:06:22Z","timestamp":1754406382000},"page":"2011-2015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8979-3972","authenticated-orcid":false,"given":"H\u00e9lo\u00efse","family":"Bourien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Adhoute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Campillo-Gimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Bouattour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Assenat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Nahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Oberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Saviano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Decaens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9548-6522","authenticated-orcid":false,"given":"Alexandre","family":"Harl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-0212","authenticated-orcid":false,"given":"Thierry","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ternant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6731-1450","authenticated-orcid":false,"given":"Laure","family":"Monard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Pezzella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Blanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-7741","authenticated-orcid":false,"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.dld.2025.07.019_bib0001","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","article-title":"Systemic treatment of hepatocellular carcinoma: an EASL position paper","volume":"75","author":"Bruix","year":"2021","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.dld.2025.07.019_bib0002","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","article-title":"Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach\u2013the ALBI grade","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.dld.2025.07.019_bib0003","first-page":"1821","article-title":"A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma","volume":"36","author":"Edeline","year":"2016","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"20","key":"10.1016\/j.dld.2025.07.019_bib0004","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.dld.2025.07.019_bib0005","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.dld.2025.07.019_bib0006","article-title":"Tremelimumab plus Durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou -Alfa Ghassan","year":"2022","journal-title":"NEJM Evid"},{"issue":"17_suppl","key":"10.1016\/j.dld.2025.07.019_bib0007","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4008","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW","volume":"42","author":"Galle","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.dld.2025.07.019_bib0008","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.dld.2025.07.019_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000453","article-title":"Phase IA\/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors","volume":"8","author":"Desai","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.dld.2025.07.019_bib0010","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","article-title":"Tislelizumab vs Sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial","volume":"9","author":"Qin","year":"2023","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.dld.2025.07.019_bib0011","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study","volume":"65","author":"Marrero","year":"2016","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.dld.2025.07.019_bib0012","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/MEG.0000000000002546","article-title":"Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohort","volume":"35","author":"Nguyen-Khac","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2025.07.019_bib0013","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12072-020-10120-3","article-title":"Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis","volume":"15","author":"Blanc","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2025.07.019_bib0014","first-page":"1000","volume":"76","author":"D\u2019Alessio","year":"2022"},{"issue":"11","key":"10.1016\/j.dld.2025.07.019_bib0015","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/oncolo\/oyae142","article-title":"Atezolizumab plus bevacizumab as first-line systemic therapy for hepatocellular carcinoma: a multi-institutional cohort study","volume":"29","author":"Storandt","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.dld.2025.07.019_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221148541","article-title":"Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma","volume":"15","author":"Cheon","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"10.1016\/j.dld.2025.07.019_bib0017","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/hepr.13797","article-title":"Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice","volume":"52","author":"Tanaka","year":"2022","journal-title":"Hepatol Res Off J Jpn Soc Hepatol"},{"issue":"10","key":"10.1016\/j.dld.2025.07.019_bib0018","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1001\/jamaoncol.2023.3284","article-title":"Immune checkpoint inhibitors for child-pugh class B advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"9","author":"Xie","year":"2023","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.dld.2025.07.019_bib0019","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jamaoncol.2024.2166","article-title":"Immunotherapy vs best supportive care for patients with hepatocellular cancer with child-pugh B dysfunction","volume":"10","author":"Fulgenzi","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.dld.2025.07.019_bib0020","article-title":"Immunotherapy benefit over best supportive care in hepatocellular cancer with child-pugh B dysfunction","author":"Polwart","year":"2024","journal-title":"JAMA Oncol [Internet]"},{"key":"10.1016\/j.dld.2025.07.019_bib0021","article-title":"Immunotherapy benefit over best supportive care in hepatocellular cancer with child-pugh B dysfunction","author":"Shigematsu","year":"2024","journal-title":"JAMA Oncol [Internet]"},{"key":"10.1016\/j.dld.2025.07.019_bib0022","article-title":"Immunotherapy benefit over best supportive care in hepatocellular cancer with child-pugh B dysfunction","author":"Gil-Sierra","year":"2024","journal-title":"JAMA Oncol [Internet]"},{"issue":"3","key":"10.1016\/j.dld.2025.07.019_bib0023","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.dld.2025.07.019_bib0024","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.dld.2025.07.019_bib0025","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/0272989X08327332","article-title":"Early stopping rules in clinical trials based on sequential monitoring of serious adverse events","volume":"29","author":"Kramar","year":"2009","journal-title":"Med Decis Making"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825009284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825009284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T04:25:46Z","timestamp":1758601546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865825009284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1590865825009284"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2025.07.019","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function score: The UCGI 41 HESTIA TRIAL DESIGN AND PRELIMINARY SAFETY Data","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}